Alternatives to Fiasp if You Can't Fill Your Prescription

With the Fiasp FlexTouch pen shortage continuing into 2026, some patients cannot fill their prescription despite trying multiple pharmacies. If you're in that situation, you have options — and several rapid-acting insulins can serve as effective alternatives to Fiasp, depending on your specific needs.

This guide covers the main Fiasp alternatives, what makes each one different, and key considerations to discuss with your prescriber before making a switch. Never switch insulins without consulting your doctor — dosing timing and response can vary between products.

What Makes Fiasp Different from Other Rapid-Acting Insulins?

Fiasp is a formulation of insulin aspart — the same active ingredient as NovoLog — but with niacinamide (vitamin B3) added to accelerate absorption. This gives Fiasp a faster onset: it appears in the bloodstream in approximately 2.5 minutes versus 5.2 minutes for NovoLog. The faster action allows Fiasp to be dosed at the start of a meal or up to 20 minutes after eating, rather than the 5–10 minutes before eating required for standard insulin aspart.

When switching from Fiasp to another rapid-acting insulin, the key adjustment is timing: other insulins typically need to be given earlier relative to meals. Your prescriber will guide you through this adjustment.

Alternative 1: NovoLog (Insulin Aspart) — Closest Switch

NovoLog is the most natural switch from Fiasp because it uses the exact same active ingredient: insulin aspart. The primary difference is that NovoLog lacks niacinamide, so it absorbs slightly more slowly. Most patients converting from Fiasp to NovoLog do so on a unit-to-unit basis (same dose, no change in units).

The main practical change: NovoLog should ideally be injected 5–10 minutes before starting a meal, rather than at meal start. This timing adjustment requires some planning but is manageable for most patients.

Availability in 2026: The NovoLog FlexTouch pen is generally available with some intermittent constraints. Note that NovoLog vials, FlexPens, and PenFill cartridges were discontinued by Novo Nordisk effective December 31, 2025 — only the FlexTouch pen remains.

Alternative 2: Humalog (Insulin Lispro) — Widely Available

Humalog, made by Eli Lilly, is the original rapid-acting insulin analog and one of the most widely available insulins in the United States. The active ingredient is insulin lispro — a different molecule from insulin aspart, but with a similar pharmacodynamic profile.

Humalog onset is approximately 15–30 minutes after injection, with peak effect at 1–2 hours and duration of 3–5 hours. It should be injected 15 minutes before or immediately after starting a meal. Humalog is available as U-100 (standard concentration) and U-200 (for patients who take larger doses), and comes in KwikPen and vial formats.

Availability: Humalog is generally well-stocked at most pharmacies and is a strong backup option if both Fiasp and NovoLog are unavailable.

Alternative 3: Lyumjev (Insulin Lispro-aabc) — Ultra-Rapid Option

Lyumjev is the most direct functional equivalent to Fiasp in terms of speed. Like Fiasp, it uses additives to accelerate absorption — in Lyumjev's case, treprostinil and citrate. It can be dosed at the start of a meal or up to 20 minutes after eating, matching Fiasp's flexible timing. The active ingredient is insulin lispro-aabc, a modified form of insulin lispro.

Lyumjev is manufactured by Eli Lilly and is approved for adults and children with type 1 or type 2 diabetes. It is available in U-100 and U-200 concentrations. If you rely specifically on Fiasp's ultra-rapid mealtime flexibility (especially important for insulin pump users or those eating unpredictably), Lyumjev may be the closest functional alternative.

Alternative 4: Biosimilars — Merilog and Kirsty

Two insulin aspart biosimilars entered the US market in 2025:

• Merilog (insulin aspart-szjj) by Sanofi — approved February 2025. Behaves like standard NovoLog (pre-meal dosing).
• Kirsty (insulin aspart-xjhz) by Biocon/Viatris — approved July 2025. Designated as interchangeable, meaning a pharmacist can substitute it for any insulin aspart product without a new prescription.

These biosimilars do not contain niacinamide, so they act more like standard NovoLog than Fiasp. They may be priced lower than brand Fiasp and are growing in availability as manufacturing scales up through 2026.

Alternative 5: Apidra (Insulin Glulisine)

Apidra, made by Sanofi, contains insulin glulisine — a different rapid-acting insulin analog. It can be injected within 15 minutes before a meal or within 20 minutes after starting a meal, similar to Fiasp's flexible timing. Apidra is available as a vial and SoloStar prefilled pen.

Side-by-Side Comparison of Fiasp Alternatives

Use this summary to guide your conversation with your prescriber:

• NovoLog: Same molecule as Fiasp, unit-for-unit switch, inject 5–10 min before meals, widely available
• Humalog: Different molecule (lispro), inject 15 min before or right after meals, very widely stocked
• Lyumjev: Ultra-rapid like Fiasp, meal-start or within 20 min, best functional equivalent for flexible timing
• Merilog/Kirsty: Insulin aspart biosimilars, like NovoLog in timing, growing availability, may be lower cost
• Apidra: Different molecule (glulisine), flexible timing like Fiasp, vial and pen available

Key Reminders When Switching Insulins

Switching rapid-acting insulins should always be done with your doctor's guidance. Here's what to keep in mind:

• Monitor blood sugar more frequently during the first week on a new insulin
• Adjust meal-to-injection timing based on the new insulin's onset profile
• If using a CGM or insulin pump, your diabetes care team may need to adjust settings
• Do not share insulin devices, even with family members using the same medication

Still looking for Fiasp itself? Learn why Fiasp is so hard to find in 2026 and use medfinder to locate pharmacies near you that can fill your prescription.